Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.74 |
| ▸ | HTR2C | P28335 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.74 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.55 |
| ▸ | DRD4 | P21917 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8004478 | 0.93 | DRD3 (0.86) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL1502267 | 0.88 | KCNH2 (0.67) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL1502213 | 0.87 | DRD3 (0.69) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL6228981 | 0.85 | DRD3 (1.00) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL29400580 | 0.85 | DRD3 (1.00) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL16417 | 0.85 | DRD3 (1.00) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3361901 | 0.85 | DRD3 (0.85) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL2369236 | 0.85 | DRD3 (0.98) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL6227991 | 0.85 | DRD3 (0.98) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 | |
| Mosapride SCHEMBL6225436 | 0.85 | DRD3 (0.98) | DRD3CYP1A2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015697-B | Amide derivatives and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO | 2015-06-17 | — | — | CN | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | DRD3 270/4885CYP1A2 1665/4885CYP3A4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.